<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867139</url>
  </required_header>
  <id_info>
    <org_study_id>2323.00</org_study_id>
    <secondary_id>6895</secondary_id>
    <nct_id>NCT00867139</nct_id>
    <nct_alias>NCT00865800</nct_alias>
  </id_info>
  <brief_title>TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients</brief_title>
  <official_title>A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of triple combination
      antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and
      to gain data on the effectiveness of TCAD
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption</measure>
    <time_frame>30 days after the final dose of study drug</time_frame>
    <description>Abnormal lab data or newly appeared symptoms &amp; signs were considered as AEs.
Examined lab data:
Blood cell count (WBC, differential count, Red Blood Cell (RBC), Hemoglobin, Hematocrit, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin Concentration (MCHC), platelets), Chemistry (Cl, bicarbonate (HCO3), K, Na), Renal function test (BUN, Creatinine, Creatinine clearance), Liver function test (AST, Alanine aminotransferase(ALT), T.Bil, gamma-glutamyltransferase)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Viral Load Decrease as a Function of Time</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Viral loads were measured by quantitative Polymerase Chain Reaction (PCR) on day 1, 3, 5, 7, 9, 15, 20 and 28, if applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Not Shedding Virus at Day 5 +/-1 and Day 10 +/- 1</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Viral Resistance as a Function of Drug Exposure</measure>
    <time_frame>28 days</time_frame>
    <description>Viral resistance was assessed within 28 days after drug administration by detecting resistance-conferring mutation genes and compared to the value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Symptoms</measure>
    <time_frame>from baseline up to 28 days</time_frame>
    <description>Calculated as the number of days (mean) any persistent symptom lasted per patient as listed below.
overall health, short of breath, chills, cough, diarrhea, ear pain, fatigue, fever, headache, hoarseness, muscle ache, phlegm, runny nose, sinus congestion, sneezing, sore throat, watery eyes, wheezing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Confirmed Pneumonia</measure>
    <time_frame>58 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>from baseline up to 58 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Supplemental Oxygen</measure>
    <time_frame>58 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ICU Admissions</measure>
    <time_frame>baseline and up to 58 days</time_frame>
    <description>The number of participants with ICU admissions was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Intubations</measure>
    <time_frame>58 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths</measure>
    <time_frame>58 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC0-last) of TCAD</measure>
    <time_frame>5 days</time_frame>
    <description>Only 5 patients had partial pharmacokinetic (PK) data available. Plasma concentration of oseltamivir was measured at several time points in one patient receiving neuraminidase inhibitor monotherapy. Plasma concentration of oseltamivir, amantadine, and ribavirin were measured at several time points in four patients receiving TCAD therapy. Area under the time-concentration curve up to the last measured time point (AUC0-last) was calculated from the plasma concentration-time profiles by non-compartmental analysis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>TCAD-Randomized Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuraminidase Monotherapy Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zanamivir or Oseltamivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCAD Open Label Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TCAD for subjects who cannot tolerate or are ineligible to receive zanamivir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCAD</intervention_name>
    <description>TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)</description>
    <arm_group_label>TCAD-Randomized Arm</arm_group_label>
    <other_name>Symmetrel</other_name>
    <other_name>Rebetol</other_name>
    <other_name>Tamiflu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanamivir or Oseltamivir</intervention_name>
    <description>Zanamivir or Oseltamivir</description>
    <arm_group_label>Neuraminidase Monotherapy Arm</arm_group_label>
    <other_name>Relenza</other_name>
    <other_name>Tamiflu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Open label treatment with TCAD</intervention_name>
    <description>TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)</description>
    <arm_group_label>TCAD Open Label Arm</arm_group_label>
    <other_name>Symmetrel</other_name>
    <other_name>Rebetol</other_name>
    <other_name>Tamiflu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Inclusion criteria for randomized arms (both needed):

          1. Age ≥7 years, male or female; AND

          2. Influenza infection (i.e. upper respiratory tract infection)

        ii. Inclusion criteria for open-label arm (at least one criteria required):

          1. Young age (1-6 years) with any influenza severity, proven or probable influenza A
             (H1N1)(H274Y); OR

          2. History of asthma; OR

          3. Older age (≥ 7 years), with no asthma; AND

               -  moderate to severe influenza; AND/OR

               -  failure in randomized study monotherapy arm iii. Inclusion criteria for all
                  subjects:

        1. Able to provide informed consent, or for whom consent may be provided by guardian 2.
        Immunocompromised, as defined by one of the following:

          -  Recent hematopoietic cell transplantation (HCT) (within 2 years, all conditioning
             regimens, allogeneic, autologous, syngeneic; after 2 years patients with chronic
             graft-versus-host disease (GVHD) requiring systemic treatment may be included) or
             solid organ transplantation

          -  Patients taking at least 2 immunosuppressants

          -  Patients undergoing combination chemotherapy within the past 3 month 3. One or more of
             the following:

          -  Presence of fever at time of screening of ≥ 38.0°C (≥ 100.0°F) taken orally.

          -  presence of at least one constitutional symptom (headache, myalgia, malaise, or
             fatigue) of any severity (mild, moderate, or severe),

          -  presence of at least one respiratory symptoms (e.g. cough, or sore throat) of any
             severity (mild, moderate, or severe),

          -  other flu-like symptoms, where the clinician orders a respiratory virus test including
             influenza A or B 4. Positive test for influenza A (if available) 5. Onset of illness
             no more than 5 days prior to diagnosis. 6. Females patients of child-bearing age who
             are capable of conception (i.e. previously have not undergone surgical sterilization)
             must meet the following criteria:

          -  Have been sexually abstinent or have used contraceptive agents (oral contraceptive or
             other hormonal contraceptives including vaginal rings or transdermal patches,
             intrauterine device (IUD), or barrier methods including condoms) during the 4 weeks
             prior to date of screening (3 months prior to enrollment for oral/hormonal
             contraceptives)

          -  Agree to be sexually abstinent or use contraceptive agents (oral contraceptive or
             other hormonal contraceptives including vaginal rings or transdermal patches,
             intrauterine device (IUD), or barrier methods including condoms) from the date of
             screening through 24 weeks after the last dose of study drug

        Exclusion Criteria(all subjects):

          1. Nausea that prevents taking oral medications

          2. Use of antiviral influenza medication within 10 days(unless switched from randomized
             to open-label TCAD). An exception to this exclusion criterion may be made by site
             investigators for patients admitted after hours who receive one or two initial doses
             of antiviral influenza medication prior to enrollment.

          3. Creatinine clearance (estimated by serum creatinine) less than 30 ml/min

          4. Current clinical evidence of a recognized or suspected uncontrolled non-influenza
             infectious illness with onset prior to screening

          5. Known hypersensitivity to amantadine, ribavirin, oseltamivir or zanamivir

          6. Women who are pregnant (positive serum or urine pregnancy test), who are attempting to
             become pregnant, or who are breast-feeding

          7. Psychiatric or cognitive illness, or recreational drug/alcohol use that, in the
             opinion of the principal investigator, would affect patient safety and/or compliance

          8. Uncontrolled seizure disorder or history of a seizure activity within 12 months prior
             to study participation

          9. Any significant finding in the patient's medical history or physical exam on Day 1
             that, in the opinion of the investigator, would affect patient safety or compliance
             with the dosing schedule

         10. Documented Influenza B viral co-infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Boeckh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle Children's</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Seo S, Englund JA, Nguyen JT, Pukrittayakamee S, Lindegardh N, Tarning J, Tambyah PA, Renaud C, Went GT, de Jong MD, Boeckh MJ. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther. 2013;18(3):377-86. doi: 10.3851/IMP2475. Epub 2012 Dec 21.</citation>
    <PMID>23264438</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2009</study_first_submitted>
  <study_first_submitted_qc>March 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2009</study_first_posted>
  <results_first_submitted>December 21, 2012</results_first_submitted>
  <results_first_submitted_qc>April 26, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2013</results_first_posted>
  <last_update_submitted>August 8, 2013</last_update_submitted>
  <last_update_submitted_qc>August 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Michael Boeckh</investigator_full_name>
    <investigator_title>Member, Vaccine and Infectious Disease Division</investigator_title>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Immunocompromised</keyword>
  <keyword>Antiviral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Amantadine</mesh_term>
    <mesh_term>Zanamivir</mesh_term>
    <mesh_term>Thiazole-4-carboxamide adenine dinucleotide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from subjects who had a hematopoietic cell transplantation (HCT) within 2 years or combination chemotherapy within 3 months, those with chronic graft-versus-host disease (GVHD) requiring systemic treatment after 2 years post HCT, or with GVHD taking at least 2 immunosuppressive drugs between February - September, 2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>TCAD</title>
          <description>This substudy was a randomized study comparing a triple combination antiviral drug (TCAD) therapy and oseltamivir (OSL) monotherapy in immunocompromised patients with upper respiratory tract infection due to influenza A who were over 7 years of age and who were not asthmatic.</description>
        </group>
        <group group_id="P2">
          <title>Neuraminidase Inhibitor Monotherapy</title>
          <description>This substudy was a randomized study comparing a triple combination antiviral drug (TCAD) therapy and oseltamivir (OSL) monotherapy in immunocompromised patients with upper respiratory tract infection due to influenza A who were over 7 years of age and who were not asthmatic.</description>
        </group>
        <group group_id="P3">
          <title>Open-labeled TCAD</title>
          <description>This substudy was a randomized study comparing a triple combination antiviral drug (TCAD) therapy and oseltamivir (OSL) monotherapy in immunocompromised patients with upper respiratory tract infection due to influenza A who were over 7 years of age and who were not asthmatic.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3">One open-labeled patient withdrew on day 5.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TCAD</title>
          <description>This substudy was a randomized study comparing TCAD therapy and OSL monotherapy in immunocompromised patients with upper respiratory tract infection due to influenza A who were over 7 years of age and who were not asthmatic.</description>
        </group>
        <group group_id="B2">
          <title>Neuraminidase Inhibitor Monotheraphy</title>
          <description>Neuraminidase inhibitors include zanamivir and oseltamivir phosphate in this study.</description>
        </group>
        <group group_id="B3">
          <title>Open-Labeled TCAD</title>
          <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received open-label TCAD.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.5" spread="17.7"/>
                    <measurement group_id="B2" value="17" spread="0"/>
                    <measurement group_id="B3" value="29.5" spread="26.0"/>
                    <measurement group_id="B4" value="36.3" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption</title>
        <description>Abnormal lab data or newly appeared symptoms &amp; signs were considered as AEs.
Examined lab data:
Blood cell count (WBC, differential count, Red Blood Cell (RBC), Hemoglobin, Hematocrit, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin Concentration (MCHC), platelets), Chemistry (Cl, bicarbonate (HCO3), K, Na), Renal function test (BUN, Creatinine, Creatinine clearance), Liver function test (AST, Alanine aminotransferase(ALT), T.Bil, gamma-glutamyltransferase)</description>
        <time_frame>30 days after the final dose of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>amantadine (75 mg), oseltamivir (50 mg), and ribavirin (200 mg); three times a day for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inihibitor Monotherapy</title>
            <description>oseltamivir (50 mg); three times a day for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Open-labeled TCAD</title>
            <description>amantadine (75 mg), oseltamivir (50 mg), and ribavirin (200 mg); three times a day for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption</title>
          <description>Abnormal lab data or newly appeared symptoms &amp; signs were considered as AEs.
Examined lab data:
Blood cell count (WBC, differential count, Red Blood Cell (RBC), Hemoglobin, Hematocrit, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin Concentration (MCHC), platelets), Chemistry (Cl, bicarbonate (HCO3), K, Na), Renal function test (BUN, Creatinine, Creatinine clearance), Liver function test (AST, Alanine aminotransferase(ALT), T.Bil, gamma-glutamyltransferase)</description>
          <units>number of participants with AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Viral Load Decrease as a Function of Time</title>
        <description>Viral loads were measured by quantitative Polymerase Chain Reaction (PCR) on day 1, 3, 5, 7, 9, 15, 20 and 28, if applicable.</description>
        <time_frame>baseline and 28 days</time_frame>
        <population>Three patients could not get viral load at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inhibitor Monotherapy</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Open-label TCAD</title>
            <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Viral Load Decrease as a Function of Time</title>
          <description>Viral loads were measured by quantitative Polymerase Chain Reaction (PCR) on day 1, 3, 5, 7, 9, 15, 20 and 28, if applicable.</description>
          <population>Three patients could not get viral load at baseline.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Not Shedding Virus at Day 5 +/-1 and Day 10 +/- 1</title>
        <time_frame>10 days</time_frame>
        <population>Participants assessed for viral shedding were those with available baseline viral load data.</population>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>This substudy was a randomized study comparing TCAD therapy and OSL monotherapy in immunocompromised patients with upper respiratory tract infection due to influenza A who were over 7 years of age and who were not asthmatic.</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inihibitor Monotherapy</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Open-labeled TCAD</title>
            <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Not Shedding Virus at Day 5 +/-1 and Day 10 +/- 1</title>
          <population>Participants assessed for viral shedding were those with available baseline viral load data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 5 +/-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10 +/- 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Viral Resistance as a Function of Drug Exposure</title>
        <description>Viral resistance was assessed within 28 days after drug administration by detecting resistance-conferring mutation genes and compared to the value at baseline.</description>
        <time_frame>28 days</time_frame>
        <population>One open-labeled patient withdrew on day 5.</population>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inihibitor Monotherapy</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Open-labeled TCAD</title>
            <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Viral Resistance as a Function of Drug Exposure</title>
          <description>Viral resistance was assessed within 28 days after drug administration by detecting resistance-conferring mutation genes and compared to the value at baseline.</description>
          <population>One open-labeled patient withdrew on day 5.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Symptoms</title>
        <description>Calculated as the number of days (mean) any persistent symptom lasted per patient as listed below.
overall health, short of breath, chills, cough, diarrhea, ear pain, fatigue, fever, headache, hoarseness, muscle ache, phlegm, runny nose, sinus congestion, sneezing, sore throat, watery eyes, wheezing</description>
        <time_frame>from baseline up to 28 days</time_frame>
        <population>one open labeled patient withdrew on day 5.</population>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inhibitor Monotherapy</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Open-label TCAD</title>
            <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Symptoms</title>
          <description>Calculated as the number of days (mean) any persistent symptom lasted per patient as listed below.
overall health, short of breath, chills, cough, diarrhea, ear pain, fatigue, fever, headache, hoarseness, muscle ache, phlegm, runny nose, sinus congestion, sneezing, sore throat, watery eyes, wheezing</description>
          <population>one open labeled patient withdrew on day 5.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="6.4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4.7" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Confirmed Pneumonia</title>
        <time_frame>58 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inihibitor Monotherapy</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Open-labeled TCAD</title>
            <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Confirmed Pneumonia</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization</title>
        <time_frame>from baseline up to 58 days</time_frame>
        <population>One open-labeled patient withdrew the study on day 5</population>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inihibitor Monotherapy</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Open-labeled TCAD</title>
            <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization</title>
          <population>One open-labeled patient withdrew the study on day 5</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="8.5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days on Supplemental Oxygen</title>
        <time_frame>58 days</time_frame>
        <population>One open-labeled TCAD patient withdrew on day 5.</population>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inihibitor Monotherapy</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Open-labeled TCAD</title>
            <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
          </group>
        </group_list>
        <measure>
          <title>Days on Supplemental Oxygen</title>
          <population>One open-labeled TCAD patient withdrew on day 5.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="1.4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ICU Admissions</title>
        <description>The number of participants with ICU admissions was evaluated.</description>
        <time_frame>baseline and up to 58 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inihibitor Monotherapy</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Open-labeled TCAD</title>
            <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ICU Admissions</title>
          <description>The number of participants with ICU admissions was evaluated.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Intubations</title>
        <time_frame>58 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inihibitor Monotherapy</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Open-labeled TCAD</title>
            <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Intubations</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths</title>
        <time_frame>58 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receiveTCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inihibitor Monotherapy</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Open-labeled TCAD</title>
            <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (AUC0-last) of TCAD</title>
        <description>Only 5 patients had partial pharmacokinetic (PK) data available. Plasma concentration of oseltamivir was measured at several time points in one patient receiving neuraminidase inhibitor monotherapy. Plasma concentration of oseltamivir, amantadine, and ribavirin were measured at several time points in four patients receiving TCAD therapy. Area under the time-concentration curve up to the last measured time point (AUC0-last) was calculated from the plasma concentration-time profiles by non-compartmental analysis.</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TCAD</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Neuraminidase Inhibitor Monotherapy</title>
            <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
          </group>
          <group group_id="O3">
            <title>Open-lable TCAD</title>
            <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (AUC0-last) of TCAD</title>
          <description>Only 5 patients had partial pharmacokinetic (PK) data available. Plasma concentration of oseltamivir was measured at several time points in one patient receiving neuraminidase inhibitor monotherapy. Plasma concentration of oseltamivir, amantadine, and ribavirin were measured at several time points in four patients receiving TCAD therapy. Area under the time-concentration curve up to the last measured time point (AUC0-last) was calculated from the plasma concentration-time profiles by non-compartmental analysis.</description>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304"/>
                    <measurement group_id="O2" value="1497"/>
                    <measurement group_id="O3" value="2487" spread="2770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TCAD</title>
          <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
        </group>
        <group group_id="E2">
          <title>Neuraminidase Inihibitor Monotherapy</title>
          <description>Eligible immunocompromised subjects( age&gt;6 years) positively diagnosed with influenza A who had mild respiratory symptoms were randomized to receive TCAD or neuraminidase inhibitor monotherapy.</description>
        </group>
        <group group_id="E3">
          <title>Open-labeled TCAD</title>
          <description>Subjects with moderate respiratory symptoms and/or influenza-related lower respiratory tract disease, subjects who could not tolerate zanamivir, and children aged 1-6 years received.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute GVHD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARDS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute GVHD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increased ALP and GGT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>acute GVHD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated. Limitations of this study include: small sample size pilot study; inability to enroll the projected number of patients for full analysis before the study was terminated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Boeckh MD</name_or_title>
      <organization>FHCRC</organization>
      <phone>206 667 6706</phone>
      <email>mboeckh@fhcrc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

